dc.contributor.author	Sarpong-Kumankomah, Sophia
dc.contributor.author	Contel, Maria
dc.contributor.author	Gailer, Juergen
dc.date.accessioned	2021-09-10T17:35:46Z
dc.date.available	2021-09-10T17:35:46Z
dc.date.issued	2020-05-15
dc.description.abstract	The bimetallic metal complex Titanocref exhibits relevant anticancer activity, but it is unknown if it is stable to reach target tissues intact. To gain insight, a pharmacologically relevant dose was added to human blood plasma and the mixture was incubated at 37ºC. The obtained mixture was analyzed 5 and 60 min later by size-exclusion chromatography hyphenated to an inductively coupled plasma atomic emission spectrometer (SEC-ICP-AES). We simultaneously detected several titanium (Ti), gold (Au) and sulfur (S)-peaks, which corresponded to a Ti degradation product that eluted partially, and a Au degradation product that eluted entirely bound to plasma proteins (both time points). Although ~70% of the intact Titanocref was retained on the column after 60 min, our results allowed us to establish ̶ for the first time ̶ its likely degradation pathway in human plasma at near physiological conditions. These results suggest that ~70% of Titanocref remain in plasma after 60 min, which supports results from a recent in vivo study in which mice were treated with Titanocref and revealed Ti:Au molar ratios in tumors and organs close to 1:1. Thus, our stability studies suggest that the intact drug is able to reach target tissue. Overall, our results exemplify that SEC-ICP-AES enables the execution of intermediate in vitro studies with human plasma in the context of advancing bimetallic metal-based drugs to more costly clinical studies.	en_US
dc.identifier.citation	Sarpong-Kumankomah, S., Contel, M., & Gailer, J. (2020). SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma. Journal of Chromatography B, 1145, 122093.	en_US
dc.identifier.doi	10.1016/j.jchromb.2020.122093	en_US
dc.identifier.grantnumber	Alberta Innovates Technology Futures	en_US
dc.identifier.uri	http://hdl.handle.net/1880/113839
dc.identifier.uri	https://dx.doi.org/10.11575/PRISM/39176
dc.language.iso	eng	en_US
dc.publisher	Elsevier	en_US
dc.publisher.department	Chemistry	en_US
dc.publisher.faculty	Science	en_US
dc.publisher.hasversion	acceptedVersion	en_US
dc.publisher.institution	University of Calgary	en_US
dc.publisher.institution	The City University of New York	en_US
dc.publisher.policy	https://www.elsevier.com/open-access/journal-embargo-finder/j	en_US
dc.rights	Unless otherwise indicated, this material is protected by copyright and has been made available with authorization from the copyright owner. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.	en_US
dc.title	SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma	en_US
dc.type	journal article	en_US
ucalgary.item.requestcopy	true	en_US
ucalgary.scholar.level	Faculty	en_US

SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma

Files

Original bundle

License bundle

Collections

Libraries & Cultural Resources